The efficacy of targeting IL-12p40 in mouse colitis models and treatment of monoclonal antibodies (ustekinumab and briakinumab) targeting p40 in IBD patients suggest that blocking IL-23 signaling is a promising therapeutic approach for IBD [38,57,58,59]. This evidence concerns the gene IL9 and inflammatory bowel disease.